Hello, I am hoping someone can help us understand what we might be missing prior to meeting with MO this week.
My husband was diagnosed with metastatic prostate cancer with mets to pelvic lymph node and a few spots in bones in early January 2022 at 56 years old. He was successfully treated with Triplet Therapy and has been off all meds on ADT vacation since February 2023 (full history in bio).
He still has his prostate. His PSA has been going up since August 2023. The last two checks, it was over 6. His MO did not seem concerned about those numbers because he is otherwise healthy and his first PSMA PET in November showed a possible recurrence, but contained to his prostate. No mets anywhere. However, since there was such a big jump between two recent PSA checks, another PSMA PET was ordered - and, as far as we can tell, it still looks pretty good (??) - even better than the November scan.
Just wondering how his PSA could be going up to the degree that it has, when his PSMA PET looks relatively okay as far as we can tell? I will post the most recent scan report below. Is there something we should be asking the MO about? Why would PSA be going up but PSMA PET looks the way it does?
Thank you in advance for any input and guidance.
------
February 12, 2024. Submitted body PSMA (F-18 piflufolastat) PET/CT performed originally February 2, 2024
CLINICAL STATEMENT: Prostate CA. EOD
TECHNICAL DETAILS PER OUTSIDE REPORT: Reviewed
FIELD OF VIEW: SKULL VERTEX to the upper thighs The standardized uptake values (SUV) are normalized to patient body weight and indicate the highest activity concentration (SUVmax) in a given disease site.
COMPARISON: PSMA (Ga-68 PSMA) PET/CT November14, 2023 ; different PSMA radiopharmaceutical, therefore SUV comparisons are not meaningful and therefore not reported
CORRELATION: None
FINDINGS:
HEAD/NECK: no suspicious findings
LUNGS: Unchanged right upper lobe calcified granuloma.
PLEURA/PERICARDIUM: No abnormal uptake.
THORACIC NODES: No abnormal uptake.
HEPATOBILIARY: No abnormal uptake.
SPLEEN: No abnormal uptake.
PANCREAS: No abnormal uptake.
ADRENAL GLANDS: No abnormal uptake.
KIDNEYS/URETERS/
BLADDER: Excreted tracer and physiological uptake limit PET evaluation
ABDOMINOPELVIC NODES: No abnormal uptake.
BOWEL/PERITONEUM/
MESENTERY: diverticulosis coli
PELVIC ORGANS:
Prior PSMA tracer avid lesion involving the right andposterior midline subregions of the prostate diminished in extent, scintigraphically; residual small ill-defined patch, image 270 series 12, SUV 5.4.
BONES/SOFT TISSUES:
No suspicious bone lesions
Few scattered subcentimeter sclerotic PET-negative bone lesions unchanged, probably benign
OTHER FINDINGS: None.
IMPRESSION: Non-MSKCC PSMA (F-18 piflufolastat) PET-CT February 2, 2024 submitted for MSK interpretation,
Since prior MSKCC (Ga-68) PSMA PET/CT,
1. PSMA tracer avid prostate gland disease, probably diminished in extent scintigraphically.
2. No PSMA tracer avid metastases evident elsewhere. Additional findings as above
FINAL REPORT